{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:44:21Z","timestamp":1787748261975,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06454-3","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T01:56:59Z","timestamp":1752717419000},"page":"3681-3691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance of angiogenesis-associated molecules and Immunologic characteristic in elderly patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"6454_CR1","doi-asserted-by":"publisher","first-page":"107844","DOI":"10.1016\/j.pharmthera.2021.107844","volume":"225","author":"MF Almatani","year":"2021","unstructured":"Almatani MF, Ali A, Onyemaechi S, Zhao Y, Gutierrez L, Vaikari VP, Alachkar H (2021) Strategies targeting FLT3 beyond the kinase inhibitors. Pharmacol Ther 225:107844","journal-title":"Pharmacol Ther"},{"issue":"11","key":"6454_CR2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, Lutsik P, Riedel A, Plass C, Jahn N et al (2023) Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 37(11):2187\u20132196","journal-title":"Leukemia"},{"issue":"21","key":"6454_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncol"},{"issue":"3","key":"6454_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022015832","volume":"140","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW et al (2022) Prospective comparison of outcomes with Azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 140(3):285\u2013289","journal-title":"Blood"},{"issue":"1","key":"6454_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM et al (2019) Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"7","key":"6454_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"16","key":"6454_CR7","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP et al (2022) Ivosidenib and Azacitidine in IDH1-Mutated acute myeloid leukemia. N Engl J Med 386(16):1519\u20131531","journal-title":"N Engl J Med"},{"issue":"11","key":"6454_CR8","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","volume":"10","author":"M Lubbert","year":"2023","unstructured":"Lubbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden W, Noppeney R, Griskevicius L, Neubauer A, Crysandt M, Vrhovac R et al (2023) 10-day decitabine versus 3\u2009+\u20097 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol 10(11):e879\u2013e889","journal-title":"Lancet Haematol"},{"issue":"12","key":"6454_CR9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"3","key":"6454_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 26(3):313\u2013347","journal-title":"Angiogenesis"},{"issue":"20","key":"6454_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"8","key":"6454_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW (2021) Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 18(8):527\u2013540","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"6454_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10456-020-09729-7","volume":"23","author":"L Jiang","year":"2020","unstructured":"Jiang L, Li N (2020) B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis 23(4):515\u2013529","journal-title":"Angiogenesis"},{"issue":"1","key":"6454_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-015-0181-2","volume":"34","author":"PA Assis","year":"2015","unstructured":"Assis PA, De Figueiredo-Pontes LL, Lima AS, Leao V, Candido LA, Pintao CT, Garcia AB, Saggioro FP, Panepucci RA, Chahud F et al (2015) Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. J Exp Clin Cancer Res 34(1):65","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"6454_CR15","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1038\/s41375-021-01271-9","volume":"35","author":"F Fan","year":"2021","unstructured":"Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H et al (2021) JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia 35(12):3509\u20133525","journal-title":"Leukemia"},{"issue":"6","key":"6454_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1179\/1607845413Y.0000000139","volume":"19","author":"H Haouas","year":"2014","unstructured":"Haouas H (2014) Angiogenesis and acute myeloid leukemia. Hematology 19(6):311\u2013323","journal-title":"Hematology"},{"issue":"2","key":"6454_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2010.09.009","volume":"80","author":"A Rodriguez-Ariza","year":"2011","unstructured":"Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N (2011) VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol 80(2):241\u2013256","journal-title":"Crit Rev Oncol Hematol"},{"key":"6454_CR18","doi-asserted-by":"crossref","unstructured":"Ci H, Wang X, Shen K, Du W, Zhou J, Fu Y, Dong Q, Jia H (2023) An angiogenic gene signature for prediction of the prognosis and therapeutic responses of hepatocellular carcinoma. Int J Mol Sci 24(4)","DOI":"10.3390\/ijms24043324"},{"issue":"1","key":"6454_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0304-3835(03)00350-1","volume":"200","author":"L Wang","year":"2003","unstructured":"Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H, Pei XF, Chen J, Yang S, Underhill CB et al (2003) Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 200(1):57\u201367","journal-title":"Cancer Lett"},{"issue":"8","key":"6454_CR20","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1245\/s10434-009-0533-2","volume":"16","author":"G Lal","year":"2009","unstructured":"Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA, Weigel RJ (2009) Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based cohort study in Iowa. Ann Surg Oncol 16(8):2280\u20132287","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6454_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s13058-014-0479-6","volume":"16","author":"KM Lee","year":"2014","unstructured":"Lee KM, Nam K, Oh S, Lim J, Kim YP, Lee JW, Yu JH, Ahn SH, Kim SB, Noh DY et al (2014) Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res 16(6):479","journal-title":"Breast Cancer Res"},{"issue":"20","key":"6454_CR22","doi-asserted-by":"publisher","first-page":"e113743","DOI":"10.15252\/embj.2023113743","volume":"42","author":"W Jiang","year":"2023","unstructured":"Jiang W, Zhang M, Gao C, Yan C, Gao R, He Z, Wei X, Xiong J, Ruan Z, Yang Q et al (2023) A mitochondrial EglN1-AMPKalpha axis drives breast cancer progression by enhancing metabolic adaptation to hypoxic stress. EMBO J 42(20):e113743","journal-title":"EMBO J"},{"issue":"9","key":"6454_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1593\/neo.12728","volume":"14","author":"K Bonezzi","year":"2012","unstructured":"Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, Ubezio P, Riva A, Giavazzi R, Verdin E et al (2012) Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 14(9):846\u2013854","journal-title":"Neoplasia"},{"issue":"11","key":"6454_CR24","doi-asserted-by":"publisher","first-page":"300060523121177","DOI":"10.1177\/03000605231211771","volume":"51","author":"F Tong","year":"2023","unstructured":"Tong F, Lu G, Zang J, Hao D, Xu W, Chen J, Ding Q, Xiong H (2023) FKBP5 associated CD8 T cell infiltration is a novel prognostic biomarker in luminal B breast cancer. J Int Med Res 51(11):3000605231211771","journal-title":"J Int Med Res"},{"key":"6454_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/OTT.S151286","volume":"11","author":"P Donizy","year":"2018","unstructured":"Donizy P, Pagacz K, Marczuk J, Fendler W, Maciejczyk A, Halon A, Matkowski R (2018) Upregulation of FOXP1 is a new independent unfavorable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients. Onco Targets Ther 11:1413\u20131422","journal-title":"Onco Targets Ther"},{"issue":"10","key":"6454_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/PAI.0000000000001061","volume":"30","author":"J Jiao","year":"2022","unstructured":"Jiao J, Liu Z, Li X, Li D, Zou Q, Yuan Y (2022) FOXP1 and FOXO3a are prognostic markers in gallbladder squamous cell\/adenosquamous carcinomas and adenocarcinomas. Appl Immunohistochem Mol Morphol 30(10):703\u2013712","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"6454_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"7","key":"6454_CR28","doi-asserted-by":"publisher","first-page":"101582","DOI":"10.1016\/j.jgo.2023.101582","volume":"14","author":"K Fujita","year":"2023","unstructured":"Fujita K, Lee S, Morishita T, Negoro E, Oiwa K, Hara T, Tsurumi H, Ueda T, Yamauchi T (2023) Prognostic significance of the geriatric 8 score alone and included with genetic risk group in older adults with acute myeloid leukemia. J Geriatr Oncol 14(7):101582","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"6454_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I (2020) Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest 130(4):1552\u20131564","journal-title":"J Clin Invest"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06454-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:53:16Z","timestamp":1757249596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06454-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6454"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06454-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5015900\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}